Over the Counter (OTC) Drugs Market (By Product Type: Analgesics, Cold & Cough Remedies, Digestives & Intestinal Remedies, Skin Treatment, Vitamins & Minerals, Others; By Distribution Channel: Drug Stores & Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2024-2033

The global over-the-counter (OTC) drugs market size was exhibited at USD 125.29 billion in 2023 and is projected to hit around USD 235.85 billion by 2033, growing at a CAGR of 6.53% during the forecast period of 2024 to 2033.

Over the Counter (OTC) Drugs Market Size 2024 To 2033

Key Takeaways:

  • The North America over the counter (OTC) drugs market size was valued at USD 36.96 billion in 2023.
  • By route of administration, the oral segment has accounted 37% revenue share in 2023.
  • The parenteral segment has captured 30% market share in 2023.

Over the Counter (OTC) Drugs Market by Overview 

The over-the-counter (OTC) drugs market has witnessed significant growth in recent years due to the increasing demand for self-medication, convenience, and accessibility of OTC products. OTC drugs are medications that can be purchased without a prescription, making them readily available to consumers for the treatment of minor ailments and health conditions.

Growth Factors

  • The growth of global over the counter drugs market is being driven by growing demand for self-medications and drugs. As per the Pharmacoepidemiology and Drug Safety, roughly 20% of the Spanish population uses non prescribed medication, with females being more likely to do so.
  • In addition, growing approvals for over the counter drugs is also boosting expansion of global over the counter drugs market. For example, Sanofi declared in February 2017 that the Food and Drug Administration has permitted Xyzal Allergy 24HR as an over the counter drugs for seasonal allergies. 
  • Another factor propelling the growth of global over the counter drugs market is due to cost effective in nature over the counter drugs. As per the survey published by the National Center for Biotechnology Information, over the counter drugs save the U.S. around $100 billion each year. The increase in the older population, as well as favorable regulatory measures, will boost the global over the counter drugs market’s growth pace.
  • In addition, increased patent expirations of many pharmaceuticals, resulting in their utilization as over the counter drugs, and the low cost of over the counter drugs are factors that will drive the expansion of global over the counter drugs market over the forecast period. 
  • The surge in demand for individualized drugs for minor disorders and the implementation of treatment procedures by healthcare payers are propelling the global over the counter drugs market. 
  • On the other hand, the global over the counter drugs market’s growth is predicted to be limited by rigorous government rules and lack of knowledge among individuals. Furthermore, the global over the counter drugs market is likely to benefit from increased research and development spending. 
  • The global market for over the counter drugs is fiercely competitive, with a number of prominent players. Few of the large market players are currently controlling the market in terms of market share.

Over the Counter (OTC) Drugs Market Report Scope

 Report Coverage  Details
Market Size in 2024 USD 125.29 Billion
Market Size by 2033 USD 235.85 Billion
Growth Rate From 2024 to 2033 CAGR of 6.53%
Base Year 2023
Forecast Period 2024-2033
Segments Covered Product Insights
Market Analysis (Terms Used) Value (US$ Million/Billion) or (Volume/Units)
Regional Scope North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa
Key Companies Profiled Bayer AG, Takeda Pharmaceutical Company Ltd., Pfizer, Johnson & Johnson Services Inc., Sanofi S.A., Reckitt Benckiser Group PLC, Novartis AG, Boehringer Ingelheim International GmbH, GlaxoSmithKline PLC, Mylan

 

The prescription drugs, on the other hand, can only be sold to consumers who have a valid prescription. Over the counter (OTC) drugs are the medicines that is sold directly to a consumer without any kind of prescription from a healthcare providers or doctors. Over the counter (OTC) drugs are chosen by regulatory agencies in many countries to guarantee that they contain chemicals that are safe and effective when taken without the supervision of a physician. The active pharmaceutical ingredient (API) of over the counter (OTC) drugs is usually regulated rather than the end product. Governments can freely create chemicals, or combinations of ingredients, into proprietary mixes by controlling APIs rather than specific medication formulations.

In recent years, the demand for over the counter (OTC) drugs has increased due to the COVID-19 pandemic. The cough and cold cases increased due to pandemic. The sale of cold and cough remedies was high during the outbreak. The consumers brought over the counter (OTC) drugs through online pharmacies. This is was due to social distancing norms and guidelines. The revenue and profit of online pharmacies increased during the epidemic of coronavirus. Such instances result into the growth of over the counter (OTC) drugs ma

The increased geriatric population, who are more susceptible to cough and cold, increased vehicle pollution, increased R&D activities leads to the high demand for over the counter (OTC) drugs in the market. An increase in the number of cough and cold cases, the development of sophisticated products, and the adoption of efficient treatments are expected to boost the overall market demand for over the counter (OTC) drugs.

In the future years, the over the counter (OTC) drugs market will be driven by the increasing availability and manufacturing of over the counter (OTC) drugs for a wide range of common illness problems. The demand for medicines is fueled by the recurrence of common colds and flu. Furthermore, the increased awareness and demand for weight loss and vitamin supplements products would significantly boost the over the counter (OTC) drugs market growth. Over the counter (OTC) drugs demand is expected to be fueled by cost-benefit analysis, positive results, and increased accessibility during the forecast period.

The development of knowledge about general health problems, as well as advancements in the healthcare and pharmaceutical industries, are driving the global over the counter (OTC) drugs and dietary supplements market. Furthermore, an increasing trend among individuals to choose over the counter (OTC) drugs for minor illnesses contributes to market growth. On the other hand, the Food and Drug Administration (FDA) strict restrictions governing the safety and efficacy of over the counter (OTC) drugs stifle the market growth during the forecast period.

Segments Insights:

Product Insights

Based on the product, the cold & cough remedies accounted revenue share of 25% in 2021. Due to seasonal variations, the sector is expected to dominate the market due to an increase in the occurrence of common colds and coughs among the population. Increased senior population, which is more susceptible to cough and colds, increased automobile pollution, more R&D activities, and increased awareness about advanced medications are all expected to help the cough remedies segment create larger revenue in the approaching years. An increase in the number of testing and research facilities, particularly in the pharmaceutical and biotechnology industries, would contribute to the growth of segment.

Cold and cough drugs can help to alleviate the symptoms of a regular cold. A runny nose, sore throat, coughing, and sneezing are all common cold symptoms. Cold and cough are the most prevalent illnesses in children under the age of ten and elderly population over 65, as per the Centers for Disease Control and Prevention, which is driving up demand for treatments.

  • The vitamin and dietary supplements segment was valued at USD 58.66 billion in 2023 and it is expected to grow at a CAGR of 6.3% from 2023 to 2033.
  • The cough and cold products segment was estimated at USD 16.34 billion in 2023 and it is expected to grow at a CAGR of 6.1% from 2023 to 2033.
  • The analgesics segment was accounted at USD 14.88 billion in 2023 and it is expected to grow at a CAGR of 5.7% from 2023 to 2033.

On the other hand, the analgesics is expected to grow at rapid pace during the forecast period. This is owing to the growing senior population, which is driving up demand for pain relievers, as well as the introduction of new over the counter (OTC) drugs pain relievers. Anti-inflammatory analgesics reduce inflammation, while opioid analgesics modify pain discernment in the mind. Few of the analgesics are accessible without a prescription, while others require one. The goal of better healthcare outcomes drives the global need for analgesics. This includes pain management, which necessitates a multidisciplinary approach in order to be effective. Apart from that, manufacturers’ development of opioid analgesics with abuse-deterrent qualities has resulted in a significant demand for analgesics all over the world.

Distribution Channel Insights

Based on the distribution channel, the drug stores and retail pharmacies segment dominated the market with highest market share during 2021. This is attributed to the rising number of retail pharmacies providing over the counter (OTC) drugs. Due to the growing number of retail pharmacies offering over the counter medications and growing patient preference for these items, the drug stores and retail pharmacies category is expected to account for the greatest market share over the projection period. 

  • The hospital pharmacies segment was valued at USD 21.14 billion in 2023 and it is expected to grow at a CAGR of 5.9% from 2023 to 2033.
  • The retail pharmacies segment was valued at USD 50.96 billion in 2023 and it is expected to grow at a CAGR of 5.5% from 2023 to 2033.
  • The online pharmacies segment was valued at USD 15.24 billion in 2023 and it is expected to grow at a CAGR of 6.2% from 2023 to 2033.

On the other hand, the online pharmacies segment is fastest growing segment in the over the counter (OTC) drugs market. This is attributed to the increase in internet penetration in the developing and underdeveloped regions. An online pharmacy, often known as an internet pharmacy or a mail order pharmacy, is a pharmacy that works online and provides orders to consumers by shipping firms, mail, or an online pharmacy web portal.

Key Companies & Market Share Insights

  • In August 2023, Pfizer and GlaxoSmithKline Plc., two of the world’s largest pharmaceutical corporations, announced a joint venture agreement. The goal of this agreement was to establish a leading consumer healthcare company and become the global over the counter (OTC) drugs market leader.
  • The U.S. Food and Drug Administration approved Astepro Allergy as an over the countermedicine for the temporary alleviation of nasal congestion, itchy nose, runny nose, and other respiratory infections in June 2021, according to Bayer. It is only non-steroid antihistamine nasal spray available over the counter in the U.S. for adults and children aged 6 and up. 
  • Dr. Reddy’s Laboratories Ltd. released Olopatadine Hydrochloride Ophthalmic Solution, an over the countereye allergy drop, in September 2023. 
  • Cipla Health teamed with Zomato, Swiggy, and Dunzo to deliver over the counter wellness goods to customer’s homes in India in April 2023. 
  • GSK Consumer Healthcare declared in December 2023 that it will launch a new nasal decongestant portfolio in India under the Otrivin brand. Otrivin Breathe Clean Daily Nasal Wash was also introduced. 
  • Crown and Soma Pharmaceuticals declared a collaboration in December 2023 to bring Microcyn-based sprays and gels, as well as anti-itching over the counter drugs to the U.S. market. 

Some of the prominent players in the Over the counter (OTC) drugs market include:

  • Bayer AG
  • Takeda Pharmaceutical Company Ltd.
  • Pfizer
  • Johnson & Johnson Services Inc.
  • Sanofi S.A.
  • Reckitt Benckiser Group PLC
  • Novartis AG
  • Boehringer Ingelheim International GmbH
  • GlaxoSmithKline PLC
  • Mylan

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the global over the counter (OTC) drugs market.

By Product Type

  • Vitamin and Dietary Supplements
  • Cough & Cold Products
  • Analgesics
  • Gastrointestinal Products
  • Sleep Aids
  • Otic Products
  • Wart Removers
  • Mouth Care Products
  • Ophthalmic Products
  • Botanicals
  • Antacids
  • Smoking Cessation Products
  • Feminine Care
  • Others

By Dosage Form

  • Tablets
  • Hard Capsules
  • Powders
  • Ointments
  • Soft Capsules
  • Liquids
  • Others

By Route of Administration

  • Oral
  • Parenteral
  • Topical
  • Others

By Distribution Channel

  • Drug Stores & Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Frequently Asked Questions

The global over the counter (OTC) drugs market size accounted for USD 171.49 billion in 2022 and is estimated to achieve a market size of USD 334.21 billion by 2032

The global over the counter (OTC) drugs market is expected to drive growth at a CAGR of 6.9% from 2022 to 2030.

The major players operating in the over the counter (OTC) drugs market are Bayer AG, Takeda Pharmaceutical Company Ltd., Pfizer, Johnson & Johnson Services Inc., Sanofi S.A., Reckitt Benckiser Group PLC, Novartis AG, Boehringer Ingelheim International GmbH, GlaxoSmithKline PLC, Mylan.

The growth in awareness of general health problems, as well as innovations in the healthcare and pharmaceutical industries, are driving the growth of over the counter (OTC) drugs market.

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Over the Counter (OTC) Drugs Market 

5.1. COVID-19 Landscape: Over the Counter (OTC) Drugs Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Over the Counter (OTC) Drugs Market, By Product

8.1. Over the Counter (OTC) Drugs Market, by Product Type, 2021-2030

8.1.1. Analgesics

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Cold & Cough Remedies

8.1.2.1. Market Revenue and Forecast (2021-2033)

8.1.3. Digestives & Intestinal Remedies

8.1.3.1. Market Revenue and Forecast (2021-2033)

8.1.4. Skin Treatment

8.1.4.1. Market Revenue and Forecast (2021-2033)

8.1.5. Vitamins & Minerals

8.1.5.1. Market Revenue and Forecast (2021-2033)

8.1.6. Others

8.1.6.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global Over the Counter (OTC) Drugs Market, By Distribution Channel

9.1. Over the Counter (OTC) Drugs Market, by Distribution Channel, 2021-2030

9.1.1. Drug Stores & Retail Pharmacies

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Hospital Pharmacies

9.1.2.1. Market Revenue and Forecast (2021-2033)

9.1.3. Online Pharmacies

9.1.3.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global Over the Counter (OTC) Drugs Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Forecast, by Product (2021-2033)

10.1.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.1.3. U.S.

10.1.3.1. Market Revenue and Forecast, by Product (2021-2033)

10.1.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Forecast, by Product (2021-2033)

10.1.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.2. Europe

10.2.1. Market Revenue and Forecast, by Product (2021-2033)

10.2.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.2.3. UK

10.2.3.1. Market Revenue and Forecast, by Product (2021-2033)

10.2.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.2.4. Germany

10.2.4.1. Market Revenue and Forecast, by Product (2021-2033)

10.2.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.2.5. France

10.2.5.1. Market Revenue and Forecast, by Product (2021-2033)

10.2.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Forecast, by Product (2021-2033)

10.2.6.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.3. APAC

10.3.1. Market Revenue and Forecast, by Product (2021-2033)

10.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.3.3. India

10.3.3.1. Market Revenue and Forecast, by Product (2021-2033)

10.3.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.3.4. China

10.3.4.1. Market Revenue and Forecast, by Product (2021-2033)

10.3.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.3.5. Japan

10.3.5.1. Market Revenue and Forecast, by Product (2021-2033)

10.3.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Forecast, by Product (2021-2033)

10.3.6.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.4. MEA

10.4.1. Market Revenue and Forecast, by Product (2021-2033)

10.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.4.3. GCC

10.4.3.1. Market Revenue and Forecast, by Product (2021-2033)

10.4.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.4.4. North Africa

10.4.4.1. Market Revenue and Forecast, by Product (2021-2033)

10.4.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.4.5. South Africa

10.4.5.1. Market Revenue and Forecast, by Product (2021-2033)

10.4.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Forecast, by Product (2021-2033)

10.4.6.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.5. Latin America

10.5.1. Market Revenue and Forecast, by Product (2021-2033)

10.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.5.3. Brazil

10.5.3.1. Market Revenue and Forecast, by Product (2021-2033)

10.5.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Forecast, by Product (2021-2033)

10.5.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

Chapter 11. Company Profiles

11.1. Bayer AG

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. Takeda Pharmaceutical Company Ltd.

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. Pfizer

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. Johnson & Johnson Services Inc.

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

11.5. Sanofi S.A.

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. Reckitt Benckiser Group PLC

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. Novartis AG

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. Boehringer Ingelheim International GmbH

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. GlaxoSmithKline PLC

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

11.10. Mylan

11.10.1. Company Overview

11.10.2. Product Offerings

11.10.3. Financial Performance

11.10.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers